Analysts weigh timing of Pfizer and BioNTech vaccine bid with regulators            

Jefferies healthcare trading predict a vaccine will be available in November, while other says it will be 2021 before a the US authorise one. Stock picture

Wall Street analysts and specialists are weighing the possibility that Pfizer and BioNTech may file their Covid-19 vaccine candidate with regulators by October after the pair said a late-stage Covid-19 vaccine study kicked off on Monday evening.

Pfizer shares rose 3% at one stage in the latest session on the announcement with its German partner, just hours after similar news from Moderna.